Literature DB >> 1679831

Human and non-financial costs of hospital-acquired infection.

P Davey1, C Hernanz, W Lynch, M Malek, D Byrne.   

Abstract

Measurement of morbidity from hospital-acquired infection should include the suffering of patients who are denied treatment, 'the opportunity cost of infection'. We believe that this perspective will also reveal other inefficiencies which may be easier to correct than hospital-acquired infection. Infection control should be seen as a component of quality control and not as an end in itself.

Entities:  

Mesh:

Year:  1991        PMID: 1679831     DOI: 10.1016/0195-6701(91)90007-u

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  10 in total

Review 1.  Counting the costs of drug-related adverse events.

Authors:  T J White; A Arakelian; J P Rho
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

2.  Technique for calculation of the true costs of antibiotic therapy.

Authors:  J R Kerr; J G Barr; E T Smyth; J O'Hare
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

Review 3.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

4.  Hidden costs of antibiotics.

Authors:  E T Smyth; J G Barr; G M Hogg
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

Review 5.  Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections.

Authors:  P Benfield; P Chrisp
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

Review 6.  Once-daily aminoglycoside administration in gram-negative sepsis. Economic and practical aspects.

Authors:  S E Parker; P G Davey
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

7.  The cost effectiveness of amoxicillin/clavulanic acid as antibacterial prophylaxis in abdominal and gynaecological surgery.

Authors:  P G Davey; S E Parker; I K Crombie; M Jaderberg
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

8.  Meropenem. A pharmacoeconomic review of its use in serious infections.

Authors:  S M Holliday; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

9.  Nosocomial infection in surgery wards: a controlled study of increased duration of hospital stays and direct cost of hospitalization.

Authors:  A A Vegas; V M Jodra; M L García
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

Review 10.  Use of teicoplanin in community medicine.

Authors:  A P Wilson; R N Grüneberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-09       Impact factor: 3.267

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.